Opinion|Videos|July 10, 2024
Improvement in Management of Duchenne Muscular Dystrophy in Recent Years
Author(s)Emma Ciafaloni, MD
A neurologist discusses how recent approvals of therapies for Duchenne muscular dystrophy have improved patient outcomes.
Advertisement
Video content above is prompted by the following questions:
- How have these recent approvals improved the management of Duchenne muscular dystrophy (DMD)?
- Share your experience with recent approvals in DMD.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
3
Evolving Responsibilities of Vice Chairs in Neurology Leadership: Mud Alvi, MD
4
Current Challenges and New Opportunities Ahead for Women in Neurology
5